Symptoms of polycystic kidney disease include:
- high blood pressure;
- spinal and headaches;
- feeling of fullness in the stomach;
- blood in the urine;
- kidney stones;
- infectious diseases of the urinary tract.
The cause of the disease is abnormal genes that are inherited. Depending on the type of genetic disorder, there are two main types of polycystic kidney disease: autosomal dominant disease (accounting for 90% of all cases) and autosomal recessive polycystic kidney disease.
Examination before treatment of polycystic kidney disease abroad
During diagnosis in foreign clinics, the size and number of cysts are determined, as well as the amount of healthy kidney tissue of the patient is estimated. The main diagnostic tests include ultrasound, CT and MRI.
Treatment of polycystic kidney disease abroad
For the treatment of polycystic kidney disease abroad, medications are primarily prescribed to control the main symptoms. For example, angiotensin converting enzyme inhibitors or angiotensin 2 receptor blockers are used to lower blood pressure. Pain is controlled with medications containing paracetamol. In rare cases, a doctor may recommend surgery to remove large cysts that cause pressure and pain. In clinics abroad, this surgery is performed laparoscopically, through a small incision. Minimally invasive kidney denervation (nerve resection) helps to effectively relieve pain.
Bladder or kidney infections are treated with specially selected antibiotics. If you have kidney failure, you may need dialysis or a kidney transplant. For foreign patients, foreign clinics provide organ transplantation from a living donor.
If a patient has a brain aneurysm, the choice of optimal treatment will depend on its size and location. With a small diameter of abnormal vessel expansion (less than 7 mm), careful monitoring is usually sufficient. Treatment of a large aneurysm is performed using minimally invasive surgical methods: microsurgical technique or endovascular embolization.
A new drug for the treatment of polycystic kidney disease abroad
Experimental treatment of polycystic kidney disease with the new drug Tolvaptan is being carried out in clinics abroad. The study showed that a vasopressin receptor antagonist slows down the rate of decline in kidney function in autosomal dominant polycystic disease. Usually, such patients are forced to undergo kidney transplantation or dialysis by the age of 60. Tolvaptan slows down the destruction of the organ and helps eliminate the need for surgery or dialysis. During polycystic kidney disease treatment abroad, patients can participate in clinical trials of other innovative drugs.
South Korea
China
Türkiye
